Compare TUSK & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TUSK | MXCT |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 136.2M |
| IPO Year | 2016 | 2021 |
| Metric | TUSK | MXCT |
|---|---|---|
| Price | $3.12 | $1.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 231.4K | ★ 737.4K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.32 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $44,292,000.00 | $33,026,000.00 |
| Revenue This Year | $383.90 | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | $35.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.72 | $0.64 |
| 52 Week High | $3.92 | $1.86 |
| Indicator | TUSK | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 52.11 |
| Support Level | $2.12 | $1.19 |
| Resistance Level | $3.49 | $1.33 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 35.71 | 32.89 |
Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes rental services, infrastructure services, natural sand proppant services, accommodation services, and drilling services.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.